The real-world effectiveness of low molecular weight heparin (LMWH) in preventing venous thromboembolism (VTE) among patients undergoing cancer surgery remains uncertain.
Therefore, we examined post-discharge prescription patterns and outcomes associated with LMWH use among patients who underwent surgery for gastrointestinal (GI) cancer.
